Active substanceInosineInosine
Similar drugsTo uncover
  • Inosie-F®
    solution in / in 
    Europharm (UK) Co., Ltd.     United Kingdom
  • Inosine
    solution in / in 
    Ama Pharm, OOO     China
  • Inozin-Eskom
    solution in / in 
    ESKOM NPK, OAO     Russia
  • Riboxin
    solution in / in 
    ATOLL, LLC     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    solution in / in 
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    MAKSFARM, OJSC     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    BINNOFARM, CJSC     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    OZONE, LLC     Russia
  • Riboxin
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Riboxin
    solution in / in 
    BIOSINTEZ, PAO     Russia
  • Riboxin
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Riboxin
    capsules inwards 
    MINSKINTERKAPS, UP     Republic of Belarus
  • Riboxin
    solution in / in 
    VEROPHARM SA     Russia
  • Riboxin
    pills inwards 
    Mapichem AG     Switzerland
  • Riboxin
    solution in / in 
    Mapichem AG     Switzerland
  • Riboxin
    solution in / in 
    DALHIMFARM, OJSC     Russia
  • Riboxin
    solution in / in 
    ELLARA, LTD.     Russia
  • Riboxin
    solution in / in 
    GROTEKS, LLC     Russia
  • Riboxin
    solution in / in 
    VELFARM, LLC     Republic of San Marino
  • Riboxin of Avexime
    pills inwards 
  • Riboxin Beefus
    solution in / in 
    UPDATE OF PFC, CJSC     Russia
  • Riboxin-Vial
    solution in / in 
    VIAL, LLC     Russia
  • Riboxin-LexT
    pills inwards 
  • Riboxin-Ferein
    pills inwards 
    BRYNTSALOV-A, CJSC     Russia
  • ASFARMA, LLC     Russia
  • Dosage form: & nbspsolution for intravenous administration
    Composition:

    1 ml of the preparation contains:


    Active substance:


    Inosine (Riboxin)

    20 mg

    Excipients:


    Methenamine

    2 mg

    1 M sodium hydroxide solution

    to pH 7.8-8.6

    Water for injections

    up to 1 ml

    Description:

    Transparent or almost transparent colorless or slightly colored liquid.

    Pharmacotherapeutic group:Metabolic means.
    ATX: & nbsp
  • Other drugs for the treatment of heart disease
  • Pharmacodynamics:

    Riboxin is a derivative (nucleoside) of purine, a precursor of adenosine triphosphate (ATP). Refers to a group of drugs that regulate metabolic processes.

    Has antihypoxic and antiarrhythmic effect. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative kidney ischemia. It takes a direct part in the exchange of glucose and promotes the activation of metabolism under conditions of hypoxia and in the absence of ATP. Activates the metabolism of pyruvic acid, which is necessary to ensure the normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle.

    Penetrating into cells, has a positive effect on metabolic processes in the myocardium - increases the strength of the heart contractions and promotes more complete relaxation of the myocardium indiastole, as a result of which the shock volume increases. The mechanism of antiarrhythmic action is not fully understood.

    Reduces platelet aggregation, activates the regeneration of tissues (especially the myocardium and mucous membrane of the gastrointestinal tract).

    Pharmacokinetics:

    Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount, it is excreted by the kidneys.

    Indications:

    In the complex therapy of coronary heart disease (after a myocardial infarction), with myocardiodystrophies, heart rhythm disorders due to the use of cardiac glycosides. In the complex therapy of liver diseases (hepatitis, cirrhosis, fatty liver disease). During an operation on an isolated kidney as a means of pharmacological protection when the circulation is turned off.

    Contraindications:

    Hypersensitivity to the drug or other derivatives of purine; gout; hyperuricemia; pregnancy; the period of breastfeeding, the age of 18 years (efficacy and safety not established).

    Carefully:

    Renal failure.

    Pregnancy and lactation:

    Riboxin is contraindicated in pregnancy.

    There is no data on the penetration of inosine into breast milk, so if it is necessary to prescribe the drug during lactation, breastfeeding should be discontinued.

    Dosing and Administration:

    Intravenously struino slowly or drip (40-60 drops in 1 min).

    Treatment begins with the introduction of 200 mg (10 ml of a solution of 20 mg / ml) 1 time per day; then, with good tolerability, the dose is increased to 400 mg (20 ml of a solution of 20 mg / ml) 1-2 times a day. Duration of treatment is 10-15 days.

    Jet injection of the drug is possible for acute heart rhythm disorders in a single dose of 200-400 mg (10-20 ml of a solution of 20 mg / ml).

    For pharmacological protection of the kidneys subjected to ischemia, Riboxin is injected intravenously in a single dose of 1200 mg (60 ml of a solution of 20 mg / ml) 5-15 minutes before clotting the renal artery, and then another 800 mg (40 ml of a solution of 20 mg / ml) immediately after the restoration of blood circulation.

    For intravenous drip, a solution of 20 mg / ml is diluted in a 5% solution of dextrose (glucose) or 0.9% solution of sodium chloride (up to 250 ml).

    The procedure for working with a polymer ampoule:

    1. Take an ampoule and shake it, holding it by the neck.
    2. Press the ampoule with your hand, while the drug should not be isolated, and rotate and separate the valve with rotating movements.
    3. Connect the syringe to the ampoule immediately through the opening.
    4.Turn the ampoule over and slowly put the contents into the syringe.
    5. Put the needle on the syringe.

    Side effects:

    Allergic reactions: skin itching, skin hyperemia, urticaria.
    Laboratory indicators: increased concentration of uric acid in the blood.
    Other: exacerbation of the gout current (with prolonged use).

    Overdose:

    At present, no cases of overdose have been reported.

    Interaction:

    When combined with cardiac glycosides, the drug can prevent the occurrence of arrhythmias, enhance the positive inotropic effect. Immunosuppressants reduce the effect of inosine.

    Special instructions:

    Riboxin is not used for emergency correction of cardiac disorders.

    When skin pruritus and skin flushing occur, treatment with the drug should be discarded. In case of renal insufficiency, the use of the drug is possible only if, in the opinion of the doctor, the expected positive effect prevails over the possible risk from use.

    During prolonged treatment, the concentration of uric acid in the blood and urine should be monitored.

    Effect on the ability to drive transp. cf. and fur:

    There are no clinical data on the effect of the drug on the ability to drive vehicles and mechanisms.

    Form release / dosage:

    Solution for intravenous administration of 20 mg / ml.

    Packaging:

    By 5 or 10 ml into ampoules of low-density polyethylene or polypropylene.

    For 10 ampoules together with instructions for use in a pack of cardboard.

    Storage conditions:

    Store at a temperature not exceeding 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date!

    Terms of leave from pharmacies:On prescription
    Registration number:LP-003524
    Date of registration:24.03.2016
    Expiration Date:24.03.2021
    The owner of the registration certificate:GROTEKS, LLC GROTEKS, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp21.08.16
    Illustrated instructions
      Instructions
      Up